Therapeutic concentrations of mitoxantrone elicit energetic imbalance in H9c2 cells as an earlier event

Cardiovascular Toxicology

Volumn 13, Issue 4, 2013, Pages 413-425

  Rossato, Luciana Grazziotin ^a   Costa, Vera Marisa ^a   Vilas Boas, Vânia ^a   De Lourdes Bastos, Maria ^a   Rolo, Anabela ^b   Palmeira, Carlos ^b   Remião, Fernando ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Cardiotoxicity; Energetic failure; Energetic imbalance; Mitoxantrone; Oxidative stress

Indexed keywords

ACETYLCYSTEINE; CASPASE 3; CYTOCHROME P450; GLUTATHIONE DISULFIDE; LACTATE DEHYDROGENASE; MALONALDEHYDE; MITOXANTRONE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE;

ARTICLE; CALCIUM CELL LEVEL; CELL DAMAGE; CELL ENERGY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG EFFECT; ENZYME ACTIVITY; ENZYME ASSAY; HYPERPOLARIZATION; MITOCHONDRIAL MEMBRANE POTENTIAL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENERGY METABOLISM; MITOXANTRONE; MYOCYTES, CARDIAC; RATS; TIME FACTORS;

EID: 84890559945     PISSN: 15307905     EISSN: 15590259     Source Type: Journal    
DOI: 10.1007/s12012-013-9224-0     Document Type: Article

References (42)

1. Seiter, K. (2005). Toxicity of the topoisomerase II inhibitors. Expert Opinion on Drug Safety, 4, 219-234.
2. Kingwell, E.; Koch, M.; Leung, B.; Isserow, S.; Geddes, J.; Rieckmann, P.; et al. (2010). Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Neurology, 74, 1822-1826.
3. Khan, S. N.; Lai, S. K.; Kumar, P.; & Khan, A. U. (2010). Effect of mitoxantrone on proliferation dynamics and cell cycle progression. Bioscience Reports, 30, 375-381.
4. Hajihassan, Z.; & Rabbani-Chadegani, A. (2011). Interaction of mitoxantrone, as an anticancer drug, with chromatin proteins, core histones and H1, in solution. International Journal of Biological Macromolecules, 48, 87-92.
5. Alderton, P. M.; Gross, J.; & Green, M. D. (1992). Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Research, 52, 194-201.
6. Batra, V. K.; Morrison, J. A.; Woodward, D. L.; Siverd, N. S.; & Yacobi, A. (1986). Pharmacokinetics of mitoxantrone in man and laboratory animals. Drug Metabolism Reviews, 17, 311-329.
7. Sereno, M.; Brunello, A.; Chiappori, A.; Barriuso, J.; Casado, E.; Belda, C.; et al. (2008). Cardiac toxicity: Old and new issues in anti-cancer drugs. Clinical and Translational Oncology, 10, 35-46.
8. Wallace, K. B. (2003). Doxorubicin-induced cardiac mitochondrionopathy. Pharmacology and Toxicology, 93, 105-115.
9. Brück, T. B.; & Brück, D. W. (2011). Oxidative metabolism of the anti-cancer agent mitoxantrone by horseradish, lacto-and lignin peroxidase. Biochimie, 93, 217-226.
10. Duthie, S. J.; & Grant, M. H. (1989). The role of reductive and oxidative metabolism in the toxicity of mitoxantrone, adriamycin and menadione in human liver derived Hep G2 hepatoma cells. British Journal of Cancer, 60, 566-571.
11. Panousis, C.; Kettle, A.; & Phillips, D. R. (1995). Myeloperoxidase oxidises mitoxantrone to metabolites which bind covalently DNA and RNA. Anticancer drug designer, 10, 593-605.
12. Mewes, K.; Blanz, J.; Ehninger, G.; Gebhardt, R.; & Zeller, K. P. (1993). Cytochrome P-450-induced cytotoxicity of mitoxantrone by formation of electrophilic intermediates. Cancer Research, 53, 5135-5142.
13. Li, S. J.; Rodgers, E. H.; & Grant, M. H. (1995). The activity of xenobiotic enzymes and the cytotoxicity of mitoxantrone in MCF 7 human breast cancer cells treated with inducing agents. Chemico Biological Interactions, 97, 101-118.
14. Rossato, L.; Costa, V.; De Pinho, P.; Freitas, V.; Viloune, L.; Bastos, M.; et al. (2013). The metabolic profile of mitoxantrone and its relation with mitoxantrone-induced cardiotoxicity. Archives of Toxicology. doi: 10.1007/s00204-013-1040-6.
15. Shipp, N. G.; Dorr, R. T.; Alberts, D. S.; Dawson, B. V.; & Hendrix, M. (1993). Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells. Cancer Research, 53, 550-556.
16. Bachmann, E.; Weber, E.; & Zbinden, G. (1987). Effect of mitoxantrone and doxorubicin on energy metabolism of the rat heart. Cancer Treatment Reports, 71, 361-366.
17. Kimes, B. W.; & Brandt, B. L. (1976). Properties of a clonal muscle from rat heart. Experimental Cell Research, 98, 367-381.
18. Zordoky, B. N. M.; & El-Kadi, A. O. S. (2007). H9c2 cell line is a valuable in vitro model to study the drug metabolizing enzymes in the heart. Journal of Pharmacological and Toxicological Methods, 56, 317-322.
19. Costa, V. M.; Silva, R.; Ferreira, R.; Amado, F.; Carvalho, F.; Bastos, M. L.; et al. (2009). Adrenaline in pro-oxidant conditions elicits intracellular survival pathways in isolated rat cardiomyocytes. Toxicology, 257, 70-79.
20. Rossato, L. G.; Costa, V. M.; De Pinho, P. G.; Carvalho, F.; Bastos, M. L.; & Remião, F. (2011). Structural isomerization of synephrine influences its uptake and ensuing glutathione depletion in rat-isolated cardiomyocytes. Archives of Toxicology, 85, 929-939.
21. Sayed-Ahmed, M. M.; Shaarawy, S.; Shouman, S. A.; & Osman, A. M. (1999). Reversal of doxorubicin-induced cardiac metabolic damage by L-carnitine. Pharmacological Research, 39, 289-295.
22. Angeloni, C.; Spencer, J. P. E.; Leoncini, E.; Biagi, P. L.; & Hrelia, S. (2007). Role of quercetin and its in vivo metabolites in protecting H9c2 cells against oxidative stress. Biochimie, 89, 73-82.
23. Grotto, D.; Santa Maria, L. D.; Boeira, S.; Valentini, J.; Charão, M. F.; Moro, A. M.; et al. (2007). Rapid quantification of malondialdehyde in plasma by high performance liquid chromatography-visible detection. Journal of Pharmaceutical and Biomedical Analysis, 43, 619-624.
24. Costa, V. M.; Silva, R.; Ferreira, L. M.; Branco, P. S.; Carvalho, F.; Bastos, M. L.; et al. (2007). Oxidation process of adrenaline in freshly isolated rat cardiomyocytes: Formation of adrenochrome, quinoproteins, and GSH adduct. Chemical Research in Toxicology, 20, 1183-1191.
25. Floryk, D.; & HoustÄk, J. (1999). Tetramethyl rhodamine methyl ester (TMRM) is suitable for cytofluorometric measurements of mitochondrial membrane potential in cells treated with digitonin. Bioscience Reports, 19, 27-34.
26. Carvalho, M.; Remião, F.; Milhazes, N.; Borges, F.; Fernandes, E.; Monteiro, M. D. C.; et al. (2004). Metabolism is required for the expression of ecstasy-induced cardiotoxicity in vitro. Chemical Research in Toxicology, 17, 623-632.
27. Canal, P.; Attal, M.; Chatelut, E.; Guichard, S.; Huguet, F.; Muller, C.; et al. (1993). Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. Cancer Research, 53, 4850-4854.
28. Neuhaus, O.; Kieseier, B. C.; & Hartung, H.-P. (2006). Therapeutic role of mitoxantrone in multiple sclerosis. Pharmacology & Therapeutics, 109, 198-209.
29. Kluza, J.; Marchetti, P.; Gallego, M.-A.; Lancel, S.; Fournier, C.; Loyens, A.; et al. (2004). Mitochondrial proliferation during apoptosis induced by anticancer agents: Effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene, 23, 7018-7030.
30. Fisher, G. R.; & Patterson, L. H. (1992). Lack of involvement of reactive oxygen in the cytotoxicity of mitoxantrone, CI941 and ametantrone in MCF-7 cells: comparison with doxorubicin. Cancer Chemotherapy and Pharmacology, 30, 451-458.
31. Chen, F.; Lewis, W.; Hollander, J. M.; Baseler, W.; & Finkel, M. S. (2012). N-acetylcysteine reverses cardiac myocyte dysfunction in HIV-Tat proteinopathy. Journal of Applied Physiology, 113, 105-113.
32. Chen, F.; Hadfield, J.; Berzingi, C.; Hollander, J.; Miller, D.; Nichols, C.; et al. (2013). N-acetylcysteine reverses cardiac myocyte dysfunction in a rodent model of behavioral stress. Journal of Applied Physiology, 115, 514-524.
33. Arnaiz, S. L.; & Llesuy, S. (1993). Oxidative stress in mouse heart by antitumoral drugs: A comparative study of doxorubicin and mitoxantrone. Toxicology, 77, 31-38.
34. Novak, R. F.; & Kharasch, E. D. (1985). Mitoxantrone: Propensity for free radical formation and lipid peroxidation-implications for cardiotoxicity. Investigational New Drugs, 3, 95-99.
35. Dong, Z.; Saikumar, P.; Weinberg, J. M.; & Venkatachalam, M. A. (2006). Calcium in cell injury and death. Annual Review of Pathology: Mechanisms of Disease, 1, 405-434.
36. Li, R.; Beebe, T.; Cui, J.; Rouhanizadeh, M.; Ai, L.; Wang, P.; et al. (2009). Pulsatile shear stress increased mitochondrial membrane potential: Implication of Mn-SOD. Biochemical and Biophysical Research Communications, 388, 406-412.
37. Acton, B. M. (2004). Alterations in mitochondrial membrane potential during preimplantation stages of mouse and human embryo development. Molecular Human Reproduction, 10, 23-32.
38. Zammit, V. A.; Ramsay, R. R.; Bonomini, M.; & Arduini, A. (2009). Carnitine, mitochondrial function and therapy. Advanced Drug Delivery Reviews, 61, 1353-1362.
39. 2+] induced by doxorubicin in cardiac cells. European Journal of Pharmacology, 425, 117-120.
40. Newman, R.; Hacker, M.; & Krakoff, I. (1981). Amelioration of adriamycin and daunorubicin myocardial toxicity by adenosine. Cancer Research, 41, 3483-3488.
41. Costa, V. M.; Carvalho, F.; Bastos, M. L.; Carvalho, R. A.; Carvalho, M.; & Remião, F. (2011). Contribution of catecholamine reactive intermediates and oxidative stress to the pathologic features of heart diseases. Current Medical Chemistry, 18, 2272-2314.
42. Trump, B. F.; & Berezesky, I. K. (1995). Calcium-mediated cell injury and cell death. FASEB, 9, 219-228.